Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If Dynamis was a fraud they would have been prosecuted. Get real.
Calling this a big turd? The company has kept up their filings.. There has been no massive dilution... I am well aware of the track record of this Company..I say this is going to be NO turd... Guess we will see what happens in the coming weeks... Back to lurking...
Good luck to you as well... it may just get a little painful for you..
Short position as of 2/13 21,841,973... They covered a very small part of it as it rose near 5.00... My bet they started shorting again from the high 4's to under 4.00.. Like I said it will be a roller coaster ride up and down. But one day it will break out big time... The shorts will lose big IMO.. This stock is not just about a short position, although it is huge... Just read the latest news and filings. Based on what I have read their future revenue will be huge in the very near future,,, I myself am looking for 5+ within a few weeks. If the Company comes out with some more good news the shorts will be scrambling .... IMO if they wait to long to cover they will take a huge hit...
To think the shorts have to cover 24 plus million shares... Wonder what large entity made the blunder.. Nothing will stop UNIS NOW IMO
Now at 4.47.. This train is just warming up.... Lets see what happens over the next few months... IMO
Thanks for the partial fill .12 stock... Whoever you are...
Yep this one is going to be a real winner IMO...
Short INTEREST AS OF 12/31/2014 24,312,566.. prepare FOR A ROLLER COASTER RIDE TO THE TOP...
The short position is almost at its highest level. right at 24 million.. That is why the stock is flat.. They are in to deep on this one... and they will deserve what they get There is no regulation in the markets just a bunch of crooks manipulating it while the ones who are suppose to protect investors turn their sorry heads away..
http://www.nasdaq.com/symbol/unis/short-interest
4.00 IS NOTHING IT WILL GO MUCH HIGHER THEN THAT imo Short has increased to 22 million plus.. Remember 103,588,608 Total shares issued as of June 30, 2014. The trade-able float is much smaller then that.. My bet is that the short position is 50% of the trade-able float. How does one cover a stock with a average daily volume under a million and that's with the shorts flipping shares imo. This saga is not just about a short squeeze. This is about a real Company with a huge up side in revenue in the very near future.
MAJOR EXPANSION, Unilife Signs 15-Year Commercial Supply Agreement for Wearable Injectors with Sanofi
Who is Sanofi
Sanofi (SNY) -NYSE Market cap 119.93B thats (B) BILLION
http://www.in-pharmatechnologist.com/Drug-Delivery/Sanofi-Inks-Deal-for-Prefilled-Syringes-with-Unilife
http://www.fiercedrugdelivery.com/special-reports/unilife-and-novartis-hikma-astrazeneca-sanofi
Listen to the last part of this video 2014 2015 is mentioned as well as the short position
Really? Good short term trade that has expired imo
Short interest increases to 21 Million plus... They will have to cover, the higher the stock price the worse the pain. A well deserved disaster for those who shorted UNIS.. IMO
http://www.nasdaq.com/symbol/unis/short-interest
http://247wallst.com/healthcare-business/2014/10/08/unilife-finds-second-wave/
Unilife Finds Second Wave
By Chris Lange October 8, 2014 3:48 pm EDT
Print Email
inShare
Unilife Corporation (NASDAQ: UNIS) is riding the wave Wednesday as it watches its shares surf into the close. While this stock was up over 50% on Monday, a second wave is being made by a brokerage research report calling for massive upside.
Monday’s driving force was that Unilife entered into an agreement with Sanofi to be the sole provider for a minimum of 15 years of cartridge based wearable injectors for all of Sanofi’s large dose volume drugs, excluding insulin. The company expects that it will receive roughly $50 million from device customization programs relating to this deal with Sanofi and potentially more revenues with other Sanofi affiliates.
The market for wearable injectors is expected to generate $8 billion in sales by 2025, according to Alan Shortall, Chairman and CEO of Unilife.
The driving force behind the second wave of gains on Wednesday was placed upon a report from a firm named Griffin Securities, but we would point out that Griffin is far from a household name when it comes to analyst reports. The firm called this deal a total game changer for Unilife. What caught investors’ eyes is the notion that even average volume and new-product launches would be enough in net income to drive the stock to a $13.50 price target. Ultimately, the wearable injectable deal might even be enough to bring in $1 billion in annual sales.
This is a massive gain when you consider it is effectively two moves higher from the same bit of news.
Another consideration for Unilife, which was released before the Sanofi deal, is that Unilife just recently received an incremental $10 million from its debt financing agreement with OrbiMed.
Unilife saw its shares jump up almost 54% on Monday to a high of $3.34 from the previous close of $2.17. Shares remained relatively dormant on Tuesday with a range on the day of $2.53 to $2.72. However late on Wednesday, shares were up 33% to a high of $3.49 and the stock was up 21% at $3.17 shortly before the close. There had also been 8 million shares traded versus average daily volume of about 768,000. On Monday just over 7 million shares moved as well. Unilife has a 52-week trading range of $2.00 to $5.80 and its market cap is $327 million.
By Chris Lange
Read more: Unilife Finds Second Wave - Unilife Corp. (NASDAQ:UNIS) - 24/7 Wall St. http://247wallst.com/healthcare-business/2014/10/08/unilife-finds-second-wave/#ixzz3FcH7NTLm
Follow us: @247wallst on Twitter | 247wallst on Facebook
http://www.streetinsider.com/Analyst+Comments/Sanofi+News+a+Game+Changer+for+Unilife+(UNIS)+-+Griffin+Securities/9895247.html
Sanofi News a 'Game Changer' for Unilife (UNIS) - Griffin Securities
On Monday, Unilife Corporation (NASDAQ: UNIS) announced an exclusive 15-year wearable injector agreement with Sanofi (NYSE: SNY), which Griffin Securities analyst Keith Markey is calling a "game changer."
Markey notes the deal came with an undisclosed upfront payment and customization contracts worth approximately $50 million over time. Moreover, the contract is expected to begin generating commercial sales of devices to Sanofi this fiscal year.
Given Sanofi's R&D pipeline the opportunity could be large for Unilife, the analyst notes. "Based on an average volume of five million doses per drug per year at peak market penetration and a price of $25 per wearable injector, launch of just eight such agents will generate almost sufficient net income over the life of the contract to justify our $13.50 price target." Markey said.
One drug that Sanofi has that stands out to the analyst is a monoclonal antibody against an enzyme called PCSK9 to treat patients with high cholesterol levels who are not adequately treated by today's medicines. "Given the size of the hypercholesterolemia market, this medicine is the keystone of the wearable injector deal, in our opinion," the analyst highlighted. The drug has the potential to generate peak sales of roughly $1 billion per year for Unilife.
Markey said Wall Street hasn't grasped the significance of the new deal. "Based on trading activity for UNIS shares, it is obvious that Wall Street doesn't understand the value of Unilife’s 15-year, single-source commercial supply contract with Sanofi for wearable injectors," he contends. The analyst pointed to the 25% increase on the announcement but then gradual sell-off to $2.69 on Monday and continued selling to $2.62 on Tuesday. This despite the major impact on the Company's near-term financial performance which should vault the Company into the highest echelon of suppliers to the pharmaceutical industry.
The firm maintained a Buy rating and price target of $13.50
What company does not have debt for major expansion... Look at the latest news release "Unilife Signs 15-Year Commercial Supply Agreement for Wearable Injectors with Sanofi" One cannot supply product without taking major loans for a major expansion of product... Being that Sanofi signed a 15 yr supply agreement with UNIS speaks volumes.. Shorts are playing the game of bashing UNIS through their contacts but IMO will lose this battle very shortly and learn a lesson in what it feels like to lose an enormous amount of money. Trying to cover 20 plus million shares short based on UNIS LOW ISSUED AND OUTSTANDING will be interesting to watch.. Any one have a clue on how many legit free trading UNIS shares are in the float? Compare that to a 20 plus million short fall ofF a cliff and that number is much higher IMO.. A few more slaps from UNIS game over if not already with the agreement between UNIS and Sanofi.. Bottom line UNIS is expanding its operations at light speed to fulfill the demand for its product line.. Numbers don't lie.. People who sold stock they do not have will do and try anything, twist anything, to get investors to sell. Bottom line just watch this GEM over the next few months into 2015.. All IMO
To think this stock is short 20 million watch this sleeper move over the next 6 months IMO
http://www.nasdaq.com/symbol/unis/short-interest
http://finance.yahoo.com/news/unilife-corporation-announces-financial-results-200500884.html
We also look forward to completing a number of additional significant supply agreements, which have taken longer than originally anticipated to complete but are now approaching the finish line
APPOX 1/4 TOTAL OF THE TOTAL SHARES ISSUED ARE SHORT
Unilife Corporation Announces Financial Results For the Fourth Quarter and Full Fiscal Year 2014
•Revenue for the Full Fiscal Year of 2014 was $14.7 million, an increase of approximately $12 million or over 400% compared to the prior year. Deferred revenue, which is cash that has been collected and is expected to be recognized within the coming 24 months, for the Full Fiscal Year of 2014 increased to $13.3 million.
•Cash receipts from customers were $23.7 million for the Full Fiscal Year of 2014, an increase of $22.5 million compared to the prior year.
•The net operating cash flow loss was narrowed by 20% over the year before, despite a significant increase in R&D investments. Over half of the Company's total annual operating expenses were invested in R&D during the Full Fiscal Year of 2014.
•At the end of the fourth quarter of Fiscal Year 2014, Unilife had 12 active customer programs, an increase of two programs since the end of the prior quarter, across all six of its product platforms.
•Since July 1, 2014, Unilife has commenced commercial sales of the Unifill® syringe utilizing an existing commercial manufacturing line. Commercial sales of other products from the Unifill family, including the Unifill Finesse® and the Unifill Nexus™, are scheduled to commence during the middle of the 2015 fiscal year on additional manufacturing lines that are either in the process of being configured or are now operational and in the process of being qualified.
Mr. Alan Shortall, Chairman and CEO of Unilife, commented: "Fiscal 2014 was a year of rapid growth in revenue, customers, supply agreements and production capabilities. Having made significant investments in R&D during the last three years, we have achieved a critical mass in product range, capabilities and industry expertise. Those investments are now generating revenue at an attractive growth rate as we enter into and execute upon supply agreements with a growing number of pharmaceutical customers."
"During Fiscal Year 2015, we look forward to achieving significant growth in revenue via commercial sales, customization fees and upfront payments from a multitude of customers and active programs. In parallel, we expect to increase capital expenditures in response to growing customer demand while moderating our investments in R&D and keeping SG&A largely stable. We also look forward to completing a number of additional significant supply agreements, which have taken longer than originally anticipated to complete but are now approaching the finish line. Based upon current cash on hand including the recently completed ATM, along with scheduled payments under existing and imminent agreements, we feel confident that we will have sufficient cash to offset our full year operating activities for fiscal 2015," Mr. Shortall concluded.
Financial Results for the Full Fiscal Year 2014
Revenue for the Full Fiscal Year of 2014 was $14.7 million, compared to $2.7 million for the same period in 2013. Deferred revenue increased to $13.3 million as of June 30, 2014. The Company's net loss for the Full Fiscal Year of 2014 was $57.9 million, or $0.59 per share, compared to a net loss of $63.2 million, or $0.78 per share, for fiscal year 2013.
Adjusted net loss for the Full Fiscal Year of 2014 was $38.8 million, or $0.40 per share, compared to $38.0 million or $0.47 per share for the prior year. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization, interest expense and the change in fair value of financial instruments.
Unilife reported $10.8 million in total cash and restricted cash at the end of Fiscal Year 2014, which ended on June 30, 2014. This does not include $12.4 million in net proceeds generated through the completion of our ATM facility in August 2014, or other cash receipts generated by customers since July 1, 2014.
http://finance.yahoo.com/news/unilife-corporation-announces-financial-results-200500884.html
I am looking for a big win on this stock UNIS,,, Currently at 2.38.. I am betting a much higher price in the next few months and through next year..
Short interest climbs to 24 Million.
http://www.nasdaq.com/symbol/unis/short-interest
SEC do your JOB... This is so illegal it's pathetic.. These crooks are selling shares that do not exist and are not covering. They are just flipping shares.. The history of the short interest pattern speaks of obvious criminal activity..
Those articles are being written IMO because of this: http://www.nasdaq.com/symbol/unis/short-interest
Over a 22 million short as of 3/31
And now this
http://www.thestreet.com/story/12680233/1/unilife-corporation-unis-hits-back-at-short-sellers.html?puc=yahoo&cm_ven=YAHOO
Shorts are TOAST.. and desperate, and that above article as well as many others are criminal in nature. I am well aware for myself who was behind the slander.
UNIS raised $60m in debt from Orbimed at attractive terms.
http://seekingalpha.com/article/2086773-unilifes-orbimed-deal-removes-dilution-risk-and-validates-platform?source=yahoo
2/28/2014 21,507,780
OVER A 21 + MILLION SHORT...
http://www.nasdaq.com/symbol/unis/short-interest
Recent financing allows company to get to profitability in 2015 and eliminates risk of dilutive raise.
3) Should allow investors to focus on company fundamental prospects and not at attacks from shorts focused on historical issues relating to character or other business affiliations of management.
1) Provides another high pedigree caliber validation of UNIS technology & platform, adding a premiere fund to the list of prestigious Biotech/Pharma clients that have already signed contracts;
Total issued and outstanding shares 97,868,961
Short position 21,507,780
No question in my mind a huge squeeze is about to unfold IMO
Wishful thinking..
With regards to the last article being put out looks like the Shorts are getting Desperate...
With over a 20 million short I think this one will get interesting...
http://www.nasdaq.com/symbol/unis/short-interest
http://finance.yahoo.com/news/unilife-signs-agreement-global-pharmaceutical-143000895.html
Unilife Signs Agreement with Global Pharmaceutical Company Seeking to Use Ocu-Ject™ to Deliver a Drug into the Eye
Unilife will begin to generate revenue under the program in January 2014.
http://files.shareholder.com/downloads/ABEA-474G59/2899881335x0x714479/01981a4c-41b7-4633-82ee-57c1bd480599/Chairmans_Letter_1_4.pdf
With financing for him yes..
MoneyStocker1
No its more then that...
Here is my clue... You have been posting on this one shell (vhgi) since 2007... THE ONLY SHELL.. Will this post get deleted? I hope not since it is factual.. Anyone who knows the market can figure this one out..
It has changed tremendously... From just empty pasture to a working and developed mine...
That person knows nothing he bought a measly 6 thousand shares and posted 5 times.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90284802
When a company has to resort to toxic financing stay away... A Convertible Debenture is the worst form of financing and it USUALLY leads to massive dilution.. If this Company had real value they would not have to resort to toxic financing.
Amarium Technologies Inc. (PINKSHEETS: AMMG) announces that the company has completed a US$3.2 Million private placement of an unsecured convertible debenture with Westin Korrin Capital Investment Inc., a Hong Kong based investment bank. The debenture, which matures after 5 years, bears an annual interest rate of 6.5% and can be converted into common stock at a price of US$0.30 per unit after 24 months.
From the SEC SITE
By contrast, in less conventional convertible security financings, the conversion ratio may be based on fluctuating market prices to determine the number of shares of common stock to be issued on conversion. A market price based conversion formula protects the holders of the convertibles against price declines, while subjecting both the company and the holders of its common stock to certain risks. Because a market price based conversion formula can lead to dramatic stock price reductions and corresponding negative effects on both the company and its shareholders, convertible security financings with market price based conversion ratios have colloquially been called "floorless", "toxic," "death spiral," and "ratchet" convertibles.
http://www.sec.gov/answers/convertibles.htm
That has no meaning.... MM's move around as trading comes in... They can be at .05's now but in a instant move down..
I Show 203,048 .041 on the bid..
Anyone know the status of the Convertible Debentures that show not converted Period End: Dec 31, 2012 filing (Annual Report). There is a bunch of them (toxic financing) To be Registered on S-1 Filing
http://www.otcmarkets.com/financialReportViewer?symbol=BION&id=102495
1245- to close central looking for a move up..
Who cares if some sell... If the stock holds strong in the morning at 9+ my bet there will be a run up in the afternoon..
Yes...
Why NOT READ the filings and take a look at all the toxic financing YET TO COVERT... This is a DOG if there ever was one....
And this stock is 0nly at .055 Not For Long IMO
Huge reverse split coming... Just a matter of time IMO When a Company dilutes the stock with toxic financing there is no regard for the investors interest..
Read the filing... Loaded with Convertible Notes;
http://app.quotemedia.com/quotetools/showFiling.go?webmasterId=89753&name=ATTITUDE%20DRINKS%20INC.:%2010-Q,%20Sub-Doc%201&link=http%3A//quotemedia.10kwizard.com/filing.xml%3Frid%3D23%26ipage%3D8738622%26DSEQ%3D1%26SQDESC%3DSECTION_BODY%26doc%3D1&cp=off&type=HTML
Toxic Convertible
Used by companies that are in such bad shape, that there is no other way to get financing. This instrument is similar to a convertible bond, but convertible at a discount to the share price at issuance and for a fixed dollar amount rather than a specific number of shares. The further the stock falls, the more shares you get. Popular in the mid to late 1990s. Also known as death spiral convertibles or floorless convertibles.